Stay updated on Durva + Domva After ChemoRad in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durva + Domva After ChemoRad in Stage III NSCLC Clinical Trial page.

Latest updates to the Durva + Domva After ChemoRad in Stage III NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now displays the PACIFIC-8 study record, including its design, eligibility criteria, study locations, and outcome measures, instead of a forbidden-access error.SummaryDifference100%

- Check19 days agoChange DetectedThe footer's site revision identifier changes from v3.7.2 to v3.8.0. The page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH notice appears above the page, linking to transition updates and describing a change in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study page now displays a 403 error with a Home button, replacing the previous study details and related information.SummaryDifference16%

Stay in the know with updates to Durva + Domva After ChemoRad in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durva + Domva After ChemoRad in Stage III NSCLC Clinical Trial page.